Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Abcam
Abcam
Activities:
Research & Development
X
LinkedIn
Trending Articles
Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant
The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Bespak and H&T Presspart announce availability of GMP pilot line for climate-friendly pMDIs
Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze
Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Axol Bioscience boosts its iPSC bioassay offering with Phenocell acquisition
The acquisition will extend Axol's range of iPSC-derived cell lines, including skin and retinal cells — while also expanding its drug discovery services
How AI and GenAI will revolutionise the healthcare industry
Artificial intelligence — and particularly its newest iteration, generative artificial intelligence (GenAI) — could bring significant changes to the way we live, work and...
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Danaher set to acquire antibody company Abcam
The two companies have entered an agreement whereby Danaher is set to acquire biotechnology company Abcam's shares for $24 per share
Manufacturing
Avacta signs distribution agreement with Abcam
Abcam supplies biological reagents and kits used in a wide range of fields including drug discovery, diagnostics and basic research
Finance
Axol Bioscience and Censo Biotechnologies announce merger
Under the terms of the agreement, Axol CEO, Liam Taylor, and the company’s senior leadership team will take over the management of the combined entity
Finance
Abingdon Health signs co-marketing agreement with Abcam
Under the terms of the agreement, Abcam will be the preferred supplier to Abingdon of gold nanoparticles and custom conjugation reagents and services
Finance
Abcam opens cell engineering facility in Bay Area
This development builds upon Abcam’s previous acquisition of a range of knockout cell lines from Edigene last year
Ingredients
Abcam offers bioactive proteins for drug discovery
Sourcing high-quality proteins with batch-to-batch consistency can be a challenge, as endotoxin levels and/or non-native protein conformations and post-translational modifications can affect safety and performance
Manufacturing
John Baker: life sciences need to address the reproducibility crisis
The head of product innovation at Abcam says it is crucial that the whole industry finds ways to de-risk the route to the patient as early as possible
Subscribe now